VEA
Virtus ETF Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-10,185
| Closed | -$68.9K | – | 599 |
|
|
2024
Q4 | $68.9K | Buy |
10,185
+422
| +4% | +$2.85K | 0.03% | 386 |
|
|
2024
Q3 | $64.3K | Buy |
9,763
+173
| +2% | +$1.14K | 0.03% | 436 |
|
|
2024
Q2 | $71.9K | Buy |
9,590
+497
| +5% | +$3.73K | 0.04% | 429 |
|
|
2024
Q1 | $90.7K | Sell |
9,093
-622
| -6% | -$6.2K | 0.05% | 380 |
|
|
2023
Q4 | $95.8K | Sell |
9,715
-317
| -3% | -$3.13K | 0.06% | 379 |
|
|
2023
Q3 | $76.7K | Sell |
10,032
-996
| -9% | -$7.62K | 0.05% | 367 |
|
|
2023
Q2 | $82.4K | Sell |
11,028
-57
| -0.5% | -$426 | 0.05% | 426 |
|
|
2023
Q1 | $73.9K | Sell |
11,085
-4,257
| -28% | -$28.4K | 0.04% | 397 |
|
|
2022
Q4 | $118K | Sell |
15,342
-1,505
| -9% | -$11.6K | 0.06% | 421 |
|
|
2022
Q3 | $179K | Buy |
16,847
+121
| +0.7% | +$1.29K | 0.07% | 330 |
|
|
2022
Q2 | $136K | Buy |
16,726
+8,405
| +101% | +$68.3K | 0.05% | 337 |
|
|
2022
Q1 | $60K | Sell |
8,321
-500
| -6% | -$3.61K | 0.03% | 359 |
|
|
2021
Q4 | $151K | Buy |
+8,821
| New | +$151K | 0.06% | 346 |
|